Sector News

Sanofi taps Bayer’s Brandicourt for CEO job

February 20, 2015
Life sciences
French pharma group Sanofi confirmed Friday it has appointed Olivier Brandicourt to be its new chief executive, four months after firing his widely-respected predecessor Chris Viehbacher.
 
Paris-educated and a French citizen, Brandicourt is seen as being more likely to avoid the kind of cultural clashes that ultimately led to the ouster of the German-Canadian Viehbacher in October. Sanofi’s board had accused Viehbacher of going behind its back with a plan for mass lay-offs in France–a politically explosive move for one of the country’s biggest employers.
 
Brandicourt also has extensive international experience, notably in the U.S., where Sanofi makes a third of its sales. He is currently head of German giant Bayer AG’s global health-care business, but spent much of his career at Pfizer Inc. He only moved to Bayer 17 months ago. Bayer has named Werner Baumann as Brandicourt’s successor at its health-care unit.
 
Despite a challenging outlook, Sanofi’s shares are testing new record highs, having more than recovered the losses that followed Viehbacher’s departure. Viehbacher had been forced out after warning that its key diabetes segment wouldn’t grow this year due to pressure from competition and to the fact that Lantus, its flagship diabetes drug, will lose patent protection in the U.S. this year.
 
By Geoffrey Smith
 
Source: Fortune

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.